Abstract 119P
Background
Small-cell lung cancer (SCLC) is a high-grade neuroendocrine tumor with a dismal prognosis and limited treatment options. Lurbinectedin, conditionally approved as a second-line treatment for metastatic SCLC, drives clinical responses in about 35% of patients. The overall survival of those who benefit from it remains very low (∼9.3 months). This highlights the need to develop improved mechanistic insight and predictive biomarkers of response.
Methods
We used human and PDX-derived SCLC cell lines to evaluate the effect of lurbinectedin in vitro. We also demonstrate the anti-tumor effect of lurbinectedin in multiple de novo and transformed SCLC PDX models. Changes in gene and protein expression pre- and post-lurbinectedin treatment were assessed by RNA sequencing and western blot analysis.
Results
Lurbinectedin markedly reduced cell viability in a majority of SCLC models with the best response on POU2F3-driven SCLC cells. We further demonstrate that lurbinectedin, either as a single agent or in combination with osimertinib, causes an appreciable anti-tumor response in multiple models of EGFR-mutant lung adenocarcinoma with histologic transformation to SCLC. Transcriptomic analysis identified induction of apoptosis, repression of EMT, modulation of PI3K/AKT, and NOTCH signaling associated with lurbinectedin response in de novo and transformed SCLC models.
Conclusions
Our study provides a mechanistic insight into lurbinectedin response in SCLC and the first demonstration that lurbinectedin is a potential therapeutic target after SCLC transformation.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract